JPM26: BMS Highlights Early-Stage Bets and Pipeline Progress Amid Late-Stage Pharma Focus

Bristol Myers Squibb (BMS) emphasized early-stage innovations at JPM26, including partnerships with insitro for ALS/FTD therapies using AI and the Orbital Therapeutics acquisition to boost cell therapy pipeline2.

BMS showcased potential blockbuster drugs like Cobenfy (neuroscience), Milvexian (cardiovascular), Admilparant (immunology), and Pumitamig (oncology), with 13 drugs expecting NME registrational data from 2026-202815.

CEO Christopher Boerner expressed confidence in navigating the 2030 patent cliff for Opdivo and Eliquis via six new 2026 medicines and pivotal readouts for assets like admilparant in IPF and milvexian in atrial fibrillation17.

BMS announced positive Phase 3 SCOUT-HCM topline results for Camzyos in adolescents with symptomatic obstructive hypertrophic cardiomyopathy on January 12, 202617.

Despite pharma's late-stage deal frenzy, BMS Chief Research Officer Robert Plenge highlighted ongoing early bets like Karuna Therapeutics (Cobenfy and muscarinic pathways) to build future blockbusters2.

Sources:

1. https://www.pharmexec.com/view/jp-morgan-2026-bristol-myers-squibb-focuses-next-decade

2. https://www.biospace.com/business/jpm26-bmss-early-stage-bets-are-happening-now-amid-pharmas-late-stage-frenzy

5. https://www.biopharmadive.com/news/jpm26-china-biotech-pfizer-obesity-bristol-sarepta-elevidys-sales/809320/

7. https://www.pharmaceutical-technology.com/news/jpm26-bms-places-confidence-in-core-pipeline-to-weather-2030-patent-cliff/